Josje Langenveld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Josje Langenveld has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
5 shared publications - Maria Gabriel Van Pampus
OLVG Department Obstetrics and Gynecology
5 shared publications - Gert-Jan van Baaren
Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, The Netherlands
4 shared publications - Kim Broekhuijsen
Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 shared publications - Henk Groen
Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications - Mallory D. Woiski
Department of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, the Netherlands
3 shared publications
Latest Publications
- 1 December 2017
- Published by Wolters Kluwer Health in Obstetric Anesthesia Digest
- Vol. 37 (4) , 183-184
Prediction of Progression to Severe Disease in Women With Late Preterm Hypertensive Disorders of Pregnancy
- 1 December 2017
- Published by Wolters Kluwer Health in Obstetric Anesthesia Digest
- Vol. 37 (4) , 183-184
Prediction of Progression to Severe Disease in Women With Late Preterm Hypertensive Disorders of Pregnancy
- 1 October 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (10) , 605-607
Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II)
Patients with hypertensive disorders of pregnancy usually have the 2 treatment options, either immediate delivery or continuing the pregnancy. Although immediately delivery of the placenta is seen as the more definitive of the 2 treatments, it does carry the potentially higher risks of an earlier birth (preterm if P = 0.005), and in a post hoc analysis, overall risk of neonatal morbidity was higher in the immediate delivery group than in the expectant monitoring group. However, neonates in the expectant monitoring group were at significantly increased risk of admission to the neonatal intensive care unit, infection or sepsis, or transient tachypnea. Although less, the risk of adverse primary maternal outcomes, as a composite, was not statistically significantly different between the 2 groups (1.1% immediate vs 3.1% expectant monitoring; relative risk, 0.36; absolute risk, 2.0; P = 0.067). HELLP syndrome was observed as the most common adverse outcome in both groups. Risk of cesarean delivery between groups also did not differ significantly. None of the adverse maternal outcomes led to neonatal complications. Immediate delivery carries significantly increased risk of adverse neonatal outcomes, such as respiratory distress syndrome. Although women with mild hypertensive disorders at 34 to 37 weeks’ gestation may benefit slightly from immediate delivery, until further studies are conducted to clarify the uncertainty, the authors recommend expectant monitoring as the primary route of treatment for this population and that immediate delivery take place only when needed.
- 1 October 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (10) , 605-607
Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II)
Patients with hypertensive disorders of pregnancy usually have the 2 treatment options, either immediate delivery or continuing the pregnancy. Although immediately delivery of the placenta is seen as the more definitive of the 2 treatments, it does carry the potentially higher risks of an earlier birth (preterm if P = 0.005), and in a post hoc analysis, overall risk of neonatal morbidity was higher in the immediate delivery group than in the expectant monitoring group. However, neonates in the expectant monitoring group were at significantly increased risk of admission to the neonatal intensive care unit, infection or sepsis, or transient tachypnea. Although less, the risk of adverse primary maternal outcomes, as a composite, was not statistically significantly different between the 2 groups (1.1% immediate vs 3.1% expectant monitoring; relative risk, 0.36; absolute risk, 2.0; P = 0.067). HELLP syndrome was observed as the most common adverse outcome in both groups. Risk of cesarean delivery between groups also did not differ significantly. None of the adverse maternal outcomes led to neonatal complications. Immediate delivery carries significantly increased risk of adverse neonatal outcomes, such as respiratory distress syndrome. Although women with mild hypertensive disorders at 34 to 37 weeks’ gestation may benefit slightly from immediate delivery, until further studies are conducted to clarify the uncertainty, the authors recommend expectant monitoring as the primary route of treatment for this population and that immediate delivery take place only when needed.
- Open Access
- 23 December 2013
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 13 (1) , 1
Erratum to: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks’ gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
- 23 December 2013
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 13 (1) , 1
Open AccessErratum to: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks’ gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
- Open Access
- 8 August 2013
- Published by Springer Nature in BMC Women's Health
- Vol. 13 (1) , 1-5
Levonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation (Novasure) in women with heavy menstrual bleeding: a multicentre randomised controlled trial
Heavy menstrual bleeding is an important health problem. Two frequently used therapies are the levonorgestrel intra-uterine system (LNG-IUS) and endometrial ablation. The LNG-IUS can be applied easily by the general practitioner, which saves costs, but has considerable failure rates. As an alternative, endometrial ablation is also very effective, but this treatment has to be performed by a gynaecologist. Due to lack of direct comparison of LNG-IUS with endometrial ablation, there is no evidence based preferred advice for the use of one of these treatment possibilities. A multicenter randomised controlled trial, organised in a network infrastructure in the Netherlands in which general practitioners and gynaecologists collaborate. Women ≥ 34 years with heavy menstrual bleeding, a Pictorial Blood Assessment Chart (PBAC) score exceeding 150 points and no future child wish can participate in the trial. After informed consent, women will be randomised to a strategy starting with a levonorgestrel releasing intrauterine system or a strategy starting with endometrial ablation. The primary outcome is the PBAC score at 24 months of follow-up. Secondary outcomes are patient satisfaction, complications, number of re-interventions, menstrual bleeding pattern, quality of life, sexual function, sick leave and costs. As predictors of effect of intervention we also meaure level of coagulation factors. This study, considering both effectiveness and cost effectiveness of LNG-IUS versus endometrial ablation may well improve care for women with heavy menstrual bleeding. Dutch trial register, number NTR2984
- 8 August 2013
- Published by Springer Nature in BMC Women's Health
- Vol. 13 (1) , 1-5
Open AccessLevonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation (Novasure) in women with heavy menstrual bleeding: a multicentre randomised controlled trial
Heavy menstrual bleeding is an important health problem. Two frequently used therapies are the levonorgestrel intra-uterine system (LNG-IUS) and endometrial ablation. The LNG-IUS can be applied easily by the general practitioner, which saves costs, but has considerable failure rates. As an alternative, endometrial ablation is also very effective, but this treatment has to be performed by a gynaecologist. Due to lack of direct comparison of LNG-IUS with endometrial ablation, there is no evidence based preferred advice for the use of one of these treatment possibilities. A multicenter randomised controlled trial, organised in a network infrastructure in the Netherlands in which general practitioners and gynaecologists collaborate. Women ≥ 34 years with heavy menstrual bleeding, a Pictorial Blood Assessment Chart (PBAC) score exceeding 150 points and no future child wish can participate in the trial. After informed consent, women will be randomised to a strategy starting with a levonorgestrel releasing intrauterine system or a strategy starting with endometrial ablation. The primary outcome is the PBAC score at 24 months of follow-up. Secondary outcomes are patient satisfaction, complications, number of re-interventions, menstrual bleeding pattern, quality of life, sexual function, sick leave and costs. As predictors of effect of intervention we also meaure level of coagulation factors. This study, considering both effectiveness and cost effectiveness of LNG-IUS versus endometrial ablation may well improve care for women with heavy menstrual bleeding. Dutch trial register, number NTR2984
- 1 December 2011
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 205 (6) , 540.e1-540.e7
Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry
- 1 December 2011
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 205 (6) , 540.e1-540.e7
Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry
- Open Access
- 7 July 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 50
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.
- 7 July 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 50
Open AccessInduction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.
- 19 February 2010
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 27 (07) , 565-571
Recurrence Risk of a Delivery before 34 Weeks of Pregnancy Due to an Early Onset Hypertensive Disorder: A Systematic Review
Early onset hypertensive disorders of pregnancy are associated with adverse maternal and neonatal outcome. The risk of recurrence influences parents' choices on subsequent pregnancies and the counseling obstetrician, but evidence so far has been limited. We performed the first systematic review on the risk of recurrence of hypertensive disorders that had caused delivery <34 weeks. We searched Medline, Embase, and the Cochrane Library for articles published until September 2009 that report on pregnancy outcome after an earlier pregnancy complicated by early hypertension, preeclampsia, or hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, which resulted in a delivery before 34 weeks. Recurrence rates of premature deliveries due to hypertensive disorders were calculated for each study separately. Pooled data were calculated. The search retrieved 36 relevant articles, of which 11 fulfilled the inclusion criteria. These 11 studies reported on 2377 patients (range 18 to 1754 patients per study), who had 2461 deliveries. Seven studies were included for further calculation. The pooled risk of a delivery before 34 weeks due to recurrence of hypertension, preeclampsia, or HELLP was 7.8% (95% confidence interval 6.7 to 9.0%). Opposed to some previous studies, the overall recurrence rate is generally low. The pooled recurrence risk of an early onset hypertensive disorder is ~8%.
- 19 February 2010
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 27 (07) , 565-571
Recurrence Risk of a Delivery before 34 Weeks of Pregnancy Due to an Early Onset Hypertensive Disorder: A Systematic Review
Early onset hypertensive disorders of pregnancy are associated with adverse maternal and neonatal outcome. The risk of recurrence influences parents' choices on subsequent pregnancies and the counseling obstetrician, but evidence so far has been limited. We performed the first systematic review on the risk of recurrence of hypertensive disorders that had caused delivery <34 weeks. We searched Medline, Embase, and the Cochrane Library for articles published until September 2009 that report on pregnancy outcome after an earlier pregnancy complicated by early hypertension, preeclampsia, or hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, which resulted in a delivery before 34 weeks. Recurrence rates of premature deliveries due to hypertensive disorders were calculated for each study separately. Pooled data were calculated. The search retrieved 36 relevant articles, of which 11 fulfilled the inclusion criteria. These 11 studies reported on 2377 patients (range 18 to 1754 patients per study), who had 2461 deliveries. Seven studies were included for further calculation. The pooled risk of a delivery before 34 weeks due to recurrence of hypertension, preeclampsia, or HELLP was 7.8% (95% confidence interval 6.7 to 9.0%). Opposed to some previous studies, the overall recurrence rate is generally low. The pooled recurrence risk of an early onset hypertensive disorder is ~8%.